ALKERMES PLC (ALKS)       27.18  +0.08 (+0.3%)

27.18  +0.08 (+0.3%)

IE00B56GVS15 - Common Stock - After market: 27.18 0 (0%)

ALKERMES PLC27.18

NASDAQ:ALKS (2/7/2023, 7:23:30 PM)+0.08 (+0.3%)

After market: 27.18 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-02 2022-11-02/bmo Earnings (Next) N/A N/A
Ins Owners 1.11% Inst Owners 96.22%
Market Cap 4.47B Shares 164.31M
PE 63.21 Fwd PE 76.51
Dividend Yield N/A Analysts 75.29
IPO 07-16 1991-07-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALKS Daily chart

Company Profile

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The company is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Company Info

ALKERMES PLC

Connaught HSE, 1 Burlington Road

DUBLIN DUBLIN DUBLIN 4

P: 35317728000.0

CEO: Richard F. Pops

Employees: 2211

Website: http://www.alkermes.com/

ALKS News

News Image4 days ago - Market News VideoAlkermes Larger Than S&P 500 Component DISH NetworkNews Image16 days ago - Market News VideoFirst Week of March 17th Options Trading For Alkermes (ALKS)News Imagea month ago - Market News VideoALKS Makes Bullish Cross Above Critical Moving AverageNews Imagea month ago - Alkermes plcAlkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the...

News Image2 months ago - Market News VideoNotable Tuesday Option Activity: ALKS, GFF, OLEDNews Image2 months ago - Market News VideoBullish Two Hundred Day Moving Average Cross - ALKS

ALKS Twits

Here you can normally see the latest stock twits on ALKS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example